Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0FJ3N
|
|||
| Drug Name |
Piperazine carbamate/urea derivative 2
|
|||
| Synonyms |
PMID29334795-Compound-40
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
Novartis AG
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H29N5O3
|
|||
| Canonical SMILES |
CC(C)N1CCN(CC1)C(=O)OC2CCN(CC2)C3=NC=C(C=C3)C(=O)N
|
|||
| InChI |
1S/C19H29N5O3/c1-14(2)22-9-11-24(12-10-22)19(26)27-16-5-7-23(8-6-16)17-4-3-15(13-21-17)18(20)25/h3-4,13-14,16H,5-12H2,1-2H3,(H2,20,25)
|
|||
| InChIKey |
SLFVKTUERQHULI-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Histamine H3 receptor (H3R) | Target Info | Ligand | [1] |
| Target's Patent Info | Histamine H3 receptor (H3R) | Target's Patent Info | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | Histamine receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Monoamine Transport | |||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.